Aralez Pharmaceuticals (NASDAQ:ARLZ) posted its quarterly earnings data on Tuesday, March 13th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.03), Morningstar.com reports. Aralez Pharmaceuticals had a negative net margin of 118.18% and a negative return on equity of 170.42%. The company had revenue of $28.02 million for the quarter, compared to analyst estimates of $25.75 million.
Shares of NASDAQ ARLZ traded down $0.05 during trading on Friday, hitting $1.40. 735,134 shares of the company were exchanged, compared to its average volume of 627,631. Aralez Pharmaceuticals has a 12-month low of $0.95 and a 12-month high of $2.98. The company has a quick ratio of 0.68, a current ratio of 0.78 and a debt-to-equity ratio of 18.05. The firm has a market cap of $95.15, a PE ratio of -1.17 and a beta of 1.59.
Several large investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. increased its position in shares of Aralez Pharmaceuticals by 159.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 261,606 shares of the company’s stock worth $371,000 after purchasing an additional 160,621 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Aralez Pharmaceuticals by 151.5% during the 4th quarter. Wells Fargo & Company MN now owns 686,931 shares of the company’s stock worth $975,000 after purchasing an additional 413,801 shares during the last quarter. Finally, Ballentine Partners LLC increased its position in shares of Aralez Pharmaceuticals by 166.7% during the 3rd quarter. Ballentine Partners LLC now owns 80,000 shares of the company’s stock worth $183,000 after purchasing an additional 50,000 shares during the last quarter. 17.83% of the stock is owned by hedge funds and other institutional investors.
Aralez Pharmaceuticals Company Profile
Aralez Pharmaceuticals Inc operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products primarily in cardiovascular disease, pain, and other specialty areas. It offers Yosprala for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events; Toprol-XL, a cardioselective beta-blocker indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia; Zontivity for the reduction of thrombotic cardiovascular events in patients; Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Fiorinal and Fiorinal C for the relief of tension type headaches; and Soriatane for the treatment of severe psoriasis and other disorders of keratinization.
Receive News & Ratings for Aralez Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.